242 related articles for article (PubMed ID: 36273925)
1. Hyperthermic intraperitoneal chemotherapy for epithelial ovarian cancer: A meta-analysis.
Kim SI; Kim JH; Lee S; Cho H; van Driel WJ; Sonke GS; Bristow RE; Park SY; Fotopoulou C; Lim MC
Gynecol Oncol; 2022 Dec; 167(3):547-556. PubMed ID: 36273925
[TBL] [Abstract][Full Text] [Related]
2. Prognostic value and adverse events of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy in primary advanced and platinum-sensitive recurrent epithelial ovarian cancer: a systematic review and meta-analysis.
Xia Y; Wang H; Zhang J; Wang Y
Int J Hyperthermia; 2023; 40(1):2165729. PubMed ID: 36775583
[TBL] [Abstract][Full Text] [Related]
3. Cytoreductive Surgery (CRS) Combined With Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Platinum-Sensitive Recurrence Epithelial Ovarian Cancer With HRR Mutation: A Phase III Randomized Clinical Trial.
Qi Y; Zhang Y; Shi Y; Yao S; Dai M; Cai H
Technol Cancer Res Treat; 2022; 21():15330338221104565. PubMed ID: 35929135
[No Abstract] [Full Text] [Related]
4. Laparoscopic versus open approach for interval cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) in advanced epithelial ovarian cancer: a matched comparative study.
Durán-Martínez M; Gómez-Dueñas G; Rodriguez-Ortíz L; Sanchez-Hidalgo JM; Gordón-Suárez A; Casado-Adam Á; Rufián-Peña S; Valenzuela-Molina F; Rufián-Andujar B; Vázquez-Borrego MC; Romero-Ruiz A; Briceño-Delgado J; Arjona-Sánchez Á
Surg Endosc; 2024 Jan; 38(1):66-74. PubMed ID: 37903884
[TBL] [Abstract][Full Text] [Related]
5. Effect of hyperthermic intraperitoneal chemotherapy in combination with cytoreductive surgery on the prognosis of patients with colorectal cancer peritoneal metastasis: a systematic review and meta-analysis.
Li J; Wang AR; Chen XD; Zhang YX; Pan H; Li SQ
World J Surg Oncol; 2022 Jun; 20(1):200. PubMed ID: 35701802
[TBL] [Abstract][Full Text] [Related]
6. Ten-year treatment outcomes of consolidation hyperthermic intraperitoneal chemotherapy for ovarian cancer (HIPEC-KOV-03R).
Yoo JG; Kim JH; Park EY; Kim I; Lim MC; Lee SJ
J Gynecol Oncol; 2023 Nov; 34(6):e72. PubMed ID: 37417300
[TBL] [Abstract][Full Text] [Related]
7. Hyperthermic Intraperitoneal Chemotherapy in the Management of Primary Epithelial Ovarian Cancer: A Debated Issue for Gynecologic Oncologists.
Gadducci A; Cosio S; Lippolis PV
Anticancer Res; 2022 Oct; 42(10):4659-4665. PubMed ID: 36191972
[TBL] [Abstract][Full Text] [Related]
8. Outcomes for Elderly Ovarian Cancer Patients Treated with Cytoreductive Surgery Plus Hyperthermic Intraperitoneal Chemotherapy (CRS/HIPEC).
Zambrano-Vera K; Sardi A; Lopez-Ramirez F; Sittig M; Munoz-Zuluaga C; Nieroda C; Gushchin V; Diaz-Montes T
Ann Surg Oncol; 2021 Aug; 28(8):4655-4666. PubMed ID: 33393042
[TBL] [Abstract][Full Text] [Related]
9. Survival After Hyperthermic Intraperitoneal Chemotherapy and Primary or Interval Cytoreductive Surgery in Ovarian Cancer: A Randomized Clinical Trial.
Lim MC; Chang SJ; Park B; Yoo HJ; Yoo CW; Nam BH; Park SY;
JAMA Surg; 2022 May; 157(5):374-383. PubMed ID: 35262624
[TBL] [Abstract][Full Text] [Related]
10. A retrospective analysis of secondary cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy in patients with recurrent ovarian cancer.
Yang D; Zhang Y; Gong P; Liu F; Gan Y; Bai W
J Obstet Gynaecol Res; 2023 Jul; 49(7):1795-1804. PubMed ID: 37231941
[TBL] [Abstract][Full Text] [Related]
11. Patterns of recurrence in women with advanced and recurrent epithelial ovarian cancer treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
Chambers LM; Yao M; Morton M; Gruner M; Chichura A; Horowitz M; Costales AB; Rose PG; Michener CM; Debernardo R
Gynecol Oncol; 2021 May; 161(2):389-395. PubMed ID: 33551202
[TBL] [Abstract][Full Text] [Related]
12. Mininvasive Cytoreduction Surgery plus HIPEC for Epithelial Ovarian Cancer: A Systematic Review.
Ronsini C; Pasanisi F; Greco P; Cobellis L; De Franciscis P; Cianci S
Medicina (Kaunas); 2023 Feb; 59(3):. PubMed ID: 36984422
[No Abstract] [Full Text] [Related]
13. [Meta analysis of whether cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy can improve survival in patients with colorectal cancer peritoneal metastasis].
Liu D; Wang H; Yuan ZX; Chen WW; Wu ZJ; Liu XX; Luo J; Chu LL; Li Y; Cai J
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Mar; 24(3):256-263. PubMed ID: 34645170
[No Abstract] [Full Text] [Related]
14. Hyperthermic intraperitoneal chemotherapy for recurrent epithelial ovarian cancer.
Chen WC; Huang HJ; Yang LY; Pan YB; Huang KG; Lin CT; Chen MY; Tang YH; Chang TC; Lai CH; Chou HH
Biomed J; 2022 Oct; 45(5):821-827. PubMed ID: 34656802
[TBL] [Abstract][Full Text] [Related]
15. Hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC) with primary or secondary cytoreductive surgery in the treatment of advanced epithelial ovarian cancer.
Manzanedo I; Pereira F; Pérez-Viejo E; Serrano Á; Hernández-García M; Martínez-Torres B; Rihuete-Caro C; Calzas J; Cueto M
Minerva Ginecol; 2017 Apr; 69(2):119-127. PubMed ID: 27415829
[TBL] [Abstract][Full Text] [Related]
16. Hyperthermic intraperitoneal chemotherapy (HIPEC) and cytoreductive surgery (CRS) in ovarian cancer: A systematic review and meta-analysis.
Huo YR; Richards A; Liauw W; Morris DL
Eur J Surg Oncol; 2015 Dec; 41(12):1578-89. PubMed ID: 26453145
[TBL] [Abstract][Full Text] [Related]
17. Critical Analysis of Stage IV Epithelial Ovarian Cancer Patients after Treatment with Neoadjuvant Chemotherapy followed by Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (CRS/HIPEC).
Munoz-Zuluaga CA; Sardi A; Sittig M; Gushchin V; King MC; Nieroda C; Lopez-Ramirez F; Diaz-Montes TP
Int J Surg Oncol; 2020; 2020():1467403. PubMed ID: 33381312
[TBL] [Abstract][Full Text] [Related]
18. Role of Hyperthermic Intraperitoneal Chemotherapy Combined with Cytoreductive Surgery as Consolidation Therapy for Advanced Epithelial Ovarian Cancer.
Frankinet L; Bhatt A; Alcazer V; Classe JM; Bereder JM; Meeus P; Pomel C; Mithieux F; Abboud K; Wermert R; Lavoue V; Marchal F; Glehen O; Bakrin N
Ann Surg Oncol; 2023 Jun; 30(6):3287-3299. PubMed ID: 36820940
[TBL] [Abstract][Full Text] [Related]
19. Effects of CytoReductive surgery plus hyperthermic IntraPEritoneal chemotherapy (HIPEC) versus CytoReductive surgery for ovarian cancer patients: A systematic review and meta-analysis.
Wang Y; Ren F; Chen P; Liu S; Song Z; Ma X
Eur J Surg Oncol; 2019 Mar; 45(3):301-309. PubMed ID: 30786961
[TBL] [Abstract][Full Text] [Related]
20. Hyperthermic Intraperitoneal Chemotherapy After Interval Cytoreductive Surgery for Patients With Advanced-Stage Ovarian Cancer Who Had Received Neoadjuvant Chemotherapy.
Lee JY; Lee YJ; Son JH; Kim S; Choi MC; Suh DH; Song JY; Hong DG; Kim MK; Kim JH; Chang SJ
JAMA Surg; 2023 Nov; 158(11):1133-1140. PubMed ID: 37672264
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]